Analysts did not seem very concerned by the treatment-related serious adverse event, noting that NGN-401 was well-tolerated ...

Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but ...

However, when she went to nursery the staff noticed that her speech was not developing properly. Doctors initially believed ...

Neurogene reports interim Phase 1/2 trial results for NGN-401 gene therapy in treating pediatric Rett syndrome, showing ...

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focusing on adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system, with a ...

At Neurogene, the developer of a gene therapy for Rett syndrome, expediency seems to be the priority, @adamfeuerstein writes.

Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.

Neurogene (NGNE, Financials) shares fell 35% in Tuesday's pre-market trading following the release of interim results from a ...

Neuren Pharmaceuticals (ASX:NEU), an Australian biotech focused on developing treatments for neurological disorders, has ...

New York, USA-based rare neurological disease drug developer Neurogene has announced positive interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase I/II open ...

Biotech stock Neurogene collapsed Tuesday after a patient experienced a serious side effect in the company's Rett syndrome ...

Neurogene's stock price collapsed by 34.8% in pre-market trading after announcing data from the Phase I/II Rett syndrome ...